+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Targeted Therapies Market - Global Forecast 2026-2032- Product Image
Neoantigen Targeted Therapies Market - Global Forecast 2026-2032- Product Image
Sale

Neoantigen Targeted Therapies Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896728
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neoantigen Targeted Therapies Market is projected to reach USD 6.15 Billion in 2026. It is expected to continue growing at a CAGR of 16.66%, reaching USD 15.61 Billion by 2032.

Neoantigen targeted therapies are reshaping precision oncology by focusing on tumor-specific mutations that are generally absent from healthy tissue. This approach supports highly individualized cancer vaccines, adoptive T-cell therapies, T-cell receptor programs, and combination regimens designed to direct immune activity toward patient-specific or shared tumor antigens.

The field is gaining momentum because next-generation sequencing, HLA typing, immunopeptidomics, and advanced bioinformatics can now identify actionable neoantigen candidates with greater speed and confidence. Clinical development remains complex, but the scientific rationale is strong: neoantigens can improve tumor specificity, support immune memory, and provide a differentiated path beyond conventional chemotherapy and broadly targeted biologics.

Transformative Shifts in the Neoantigen Therapy Landscape

The neoantigen targeted therapies landscape is shifting from exploratory immuno-oncology research toward scalable translational platforms. Improvements in whole-exome sequencing, RNA sequencing, single-cell analysis, and tumor microenvironment profiling are enabling developers to select more clinically relevant epitopes and design personalized therapies within commercially meaningful timelines.

Another major shift is the movement from single-modality development to rational combinations. Neoantigen vaccines and engineered cellular therapies are increasingly evaluated with immune checkpoint inhibitors, cytokine modulation, lymphodepletion strategies, or tumor microenvironment interventions. This reflects a growing recognition that antigen identification alone is not sufficient; durable response depends on antigen presentation, T-cell fitness, immune infiltration, and resistance management.

Cumulative Impact of Artificial Intelligence in Neoantigen Discovery

Artificial intelligence is becoming central to neoantigen discovery, prioritization, and manufacturing design. AI-enabled pipelines can integrate tumor DNA and RNA sequencing, HLA binding predictions, clonality assessment, antigen processing signals, and immunogenicity models to reduce the number of low-value candidates entering expensive validation workflows.

The cumulative impact of AI is also visible in clinical operations. Predictive analytics can support patient selection, trial stratification, toxicity monitoring, and adaptive protocol design. While AI models require rigorous validation across diverse HLA backgrounds and tumor types, they are accelerating the transition from data-heavy discovery to decision-ready therapeutic development.

Key Regional Insights for Neoantigen Targeted Therapies

North America remains a leading region for neoantigen targeted therapies due to its concentration of oncology biotechnology companies, academic cancer centers, contract development partners, and venture financing. The United States anchors this ecosystem through FDA-regulated clinical trial activity, broad sequencing adoption in oncology care, and strong translational research networks, while Canada contributes through cancer genomics, immunotherapy research, and publicly supported health innovation programs.

Europe benefits from established biopharmaceutical infrastructure, centralized regulatory engagement through the European Medicines Agency, and strong national oncology research systems across Germany, France, Italy, Spain, and the United Kingdom. The European Union’s emphasis on health data governance and cross-border research can support multi-country trials, although reimbursement diversity, advanced therapy manufacturing capacity, and national health technology assessment requirements remain key considerations.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, India, and ASEAN markets invest in precision medicine, clinical trial capacity, cancer genomics, and cell and gene therapy infrastructure. Latin America, led by Brazil and Mexico, offers growing oncology demand and improving clinical research participation, but access to advanced molecular diagnostics remains uneven across public and private care settings. The Middle East, especially GCC countries, is investing in genomics, specialty care, and tertiary oncology centers, while Africa represents an emerging opportunity where partnerships, pathology modernization, sequencing infrastructure, and equitable access models will determine long-term adoption.

Key Group Insights Across Global Innovation Blocs

Among major economic and geopolitical groups, the G7 holds a strong position in neoantigen targeted therapies because members combine advanced clinical trial systems, major biomedical research funding, high oncology care capacity, and deep regulatory experience. NATO countries overlap significantly with leading biomedical innovation hubs, supporting collaborative research, resilient supply chains, cold-chain logistics, and standardized approaches to advanced therapy handling.

The European Union is strategically important because it links scientific scale with harmonized regulatory pathways, clinical research networks, and data protection standards, creating a structured environment for multi-country oncology development. BRICS economies, particularly China, India, and Brazil, are increasingly relevant due to large patient populations, expanding sequencing capacity, and growing biomanufacturing capabilities, although regulatory maturity, reimbursement pathways, and access to high-complexity diagnostics vary by country.

ASEAN is becoming more attractive for clinical partnerships as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines improve oncology infrastructure, digital health adoption, and regional research connectivity. The GCC is also gaining importance through national genomics initiatives, investment in cancer centers, and demand for high-value precision oncology, creating opportunities for diagnostic-enabled therapy partnerships and specialized treatment pathways.

Key Country Insights in Neoantigen Targeted Therapy Adoption

The United States leads global commercialization potential for neoantigen targeted therapies through its advanced oncology trial ecosystem, strong venture capital base, mature regulatory framework for advanced therapies, and established reimbursement channels for high-value precision medicine. Canada complements this with cancer genomics research and publicly funded clinical networks. Mexico and Brazil are important Latin American markets where rising cancer burden and expanding private healthcare capacity support future adoption, provided molecular diagnostics, biopsy logistics, and specialized oncology access become more consistent.

In Europe, the United Kingdom, Germany, and France are prominent due to established oncology research centers, biopharma investment, genomic medicine programs, and strong clinical trial activity. Italy and Spain contribute meaningful patient recruitment capacity and specialist oncology networks, while Russia maintains scientific capabilities but faces operational and geopolitical constraints that can complicate international collaboration, technology transfer, and trial execution.

Across Asia-Pacific, China is a major force because of scale, domestic biotech growth, and investment in cell therapy, genomics, and oncology innovation. Japan and South Korea offer sophisticated regulatory systems, advanced hospitals, and strong biomanufacturing capabilities. India is increasingly relevant due to its large cancer population, expanding genomics sector, and cost-efficient clinical research environment. Australia has become a preferred early-phase oncology trial destination supported by high-quality sites, R&D incentives, experienced investigators, and strong translational research capacity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated discovery platforms that combine tumor sequencing, HLA typing, transcriptomics, immunopeptidomics, and validated AI models. Competitive advantage will come from the ability to identify clinically relevant neoantigens quickly, manufacture individualized products reliably, and prove immune activation with robust biomarker evidence.

Organizations should also build combination strategies early, particularly with checkpoint inhibitors and tumor microenvironment modulators, while designing trials around measurable residual disease, adjuvant settings, and tumor types with high mutational burden. Strategic partnerships with sequencing providers, academic cancer centers, CDMOs, and real-world data networks can reduce execution risk and improve scalability.

Commercial planning should begin before pivotal trials. Developers need clear evidence packages for payers, manufacturing cost controls, decentralized sample logistics, and region-specific access models. Because personalized therapies challenge traditional reimbursement, outcomes-based contracting and diagnostic-linked value demonstration should be evaluated early.

Research Methodology

Research methodology is developed using a structured secondary-research approach. The analysis synthesizes information from regulatory agencies, peer-reviewed oncology literature, clinical trial registries, government health programs, academic cancer center publications, and recognized scientific organizations.

Insights are evaluated for clinical relevance, technological maturity, regulatory feasibility, geographic applicability, and commercial scalability. Particular attention is given to verified developments in next-generation sequencing, personalized cancer vaccines, adoptive T-cell therapies, AI-enabled antigen prediction, biomanufacturing, and immuno-oncology combinations. The methodology emphasizes triangulation across multiple credible sources rather than reliance on a single dataset.

Conclusion

Neoantigen targeted therapies represent one of the most precise frontiers in cancer immunotherapy. The sector is advancing because sequencing, computational biology, AI, and advanced manufacturing are converging to make personalized and highly specific treatment strategies more feasible.

The next phase of leadership will depend on evidence quality, speed of manufacturing, biomarker-defined patient selection, and the ability to demonstrate durable clinical benefit. Organizations that integrate scientific rigor with scalable operations and regional access planning will be best positioned to capture long-term value in this evolving precision oncology field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neoantigen Targeted Therapies Market, by Therapy Modality
7.1. Introduction
7.2. Adoptive Cell Therapy
7.2.1. CAR-T Cell Therapy
7.2.2. T Cell Receptor (TCR) Therapy
7.2.3. Tumor-infiltrating lymphocytes (TIL)
7.3. Personalized Neoantigen Vaccines
7.3.1. Dendritic Cell (DC) Vaccines
7.3.2. DNA/ RNA-based Vaccines
7.3.3. Peptide (SLP) Vaccines
8. Neoantigen Targeted Therapies Market, by Treatment Approach
8.1. Introduction
8.2. Combination Therapy
8.3. Monotherapy
9. Neoantigen Targeted Therapies Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
10. Neoantigen Targeted Therapies Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Neoantigen Targeted Therapies Market, by Target Disease Indication
11.1. Introduction
11.2. Bone Cancer
11.3. Colorectal Cancer
11.4. Gynecological Cancer
11.5. Non-Small Cell Lung Cancer
11.6. Renal Cell Carcinoma
12. Neoantigen Targeted Therapies Market, by End-User
12.1. Introduction
12.2. Academic & Government Research Institutes
12.3. Hospitals & Clinics
12.4. Specialty Clinics
13. Neoantigen Targeted Therapies Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Neoantigen Targeted Therapies Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Neoantigen Targeted Therapies Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. United Kingdom
15.5. India
15.6. Japan
15.7. Russia
15.8. Brazil
15.9. Canada
15.10. Italy
15.11. Mexico
15.12. France
15.13. Spain
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Achilles Therapeutics Limited
17.2. Agenus Inc.
17.3. AstraZeneca plc
17.4. BioNTech SE
17.5. Bristol-Myers Squibb Company
17.6. CureVac N.V.
17.7. Eli Lilly and Company
17.8. EpiVax, Inc.
17.9. F. Hoffmann-La Roche AG
17.10. Genentech, Inc.
17.11. Genocea Biosciences, Inc.
17.12. Gilead Sciences, Inc.
17.13. GlaxoSmithKline plc
17.14. Gritstone bio, Inc.
17.15. Immatics N.V.
17.16. Immunomic Therapeutics, Inc.
17.17. IOVANCE Biotherapeutics, Inc.
17.18. Medigene AG
17.19. Merck & Co., Inc.
17.20. Moderna, Inc.
17.21. Neon Therapeutics, Inc.
17.22. Nykode Therapeutics
17.23. Pfizer Inc.
17.24. Precision Biologics
17.25. Valo Therapeutics Ltd
List of Figures
FIGURE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ADOPTIVE CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ADOPTIVE CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ADOPTIVE CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL T CELL RECEPTOR (TCR) THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL T CELL RECEPTOR (TCR) THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL T CELL RECEPTOR (TCR) THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTES (TIL) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTES (TIL) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTES (TIL) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PERSONALIZED NEOANTIGEN VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PERSONALIZED NEOANTIGEN VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PERSONALIZED NEOANTIGEN VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DENDRITIC CELL (DC) VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DENDRITIC CELL (DC) VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DENDRITIC CELL (DC) VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DNA/ RNA-BASED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DNA/ RNA-BASED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DNA/ RNA-BASED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE (SLP) VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE (SLP) VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE (SLP) VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BONE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL BONE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BONE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GYNECOLOGICAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GYNECOLOGICAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GYNECOLOGICAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 118. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 120. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 121. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 122. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 123. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 125. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 126. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 138. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 139. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 140. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 141. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 142. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 143. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 144. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 145. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 146. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 147. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 151. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 152. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 153. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 154. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 156. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 157. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 158. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 159. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 161. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 162. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 163. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 164. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 165. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 166. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 167. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 168. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 181. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 182. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 183. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 184. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 186. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 187. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 188. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 189. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 191. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 192. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 193. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 194. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 196. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 198. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 199. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 201. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 202. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 203. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 204. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 205. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 206. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 207. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 208. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 209. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 220. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 221. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 222. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 223. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 224. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 225. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 226. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 227. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 228. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 229. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 230. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 232. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 233. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 234. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 235. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 237. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 238. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 239. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 250. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 252. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 253. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 254. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 255. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 256. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 257. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 258. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 259. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 260. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 262. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 263. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 264. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 265. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 267. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 269. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 282. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 283. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 284. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 285. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 287. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 288. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 289. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 290. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 292. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 293. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 294. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 295. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 297. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 298. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 299. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 300. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 302. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 303. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 304. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 305. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 307. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 308. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 309. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 310. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 311. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 312. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 313. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2017-2032 (USD MILLION)
TABLE 314. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 315. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 316. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 317. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 318. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 319. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 320. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2017-2032 (USD MILLION)
TABLE 322. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 323. FRANCE NEOANTIGEN

Companies Mentioned

  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol‑Myers Squibb Company
  • CureVac N.V.
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics N.V.
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.15 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.61 Billion
Compound Annual Growth Rate16.6%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Neoantigen Targeted Therapies Market Report 2026 - Product Image

Neoantigen Targeted Therapies Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Neoantigen Targeted Therapies - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Neoantigen Targeted Therapies - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report 2026 - Product Image

G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Global CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight 2026 - Product Image

Global CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight 2026

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.